Cynata Therapeutics (ASX:CYP) has reached a significant milestone in its lead osteoarthritis program, announcing the completion of all final participant visits in the Phase 3 SCUlpTOR trial evaluating its Cymerus-derived cell therapy, CYP-004, in knee osteoarthritis. …
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 Australian Biotech
Latest Video
New Stories
-
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measure approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News -
Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow
November 24, 2025 - - Australian Biotech -
‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - - Latest News -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News -
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - - Latest News